Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities.

Molecular strike force for the immune system

The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities.
08.12.2022 - Daniel Koller

Autoimmunity is an area rich in scope for the delivery of innovative therapies by the biotech industry. More than 100 autoimmune diseases affecting nerves, organs or muscle tissue are currently known to medical science. Autoimmune diseases are the most common form of chronic disease after heart disease and cancer, affecting 5% to 8% of the global population.

The reasons for the rise in autoimmunity are manifold. Environmental factors, overactive immune responses, and genetic causes may be factors in triggering autoimmune disease. Unmet medical need is greatest in niche autoimmune disease indications due to the complete absence of treatment options. That is not the case for chronic diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis (MS) that affect millions of people worldwide. With so many approved medicines already available for these indications, including generics and biosimilars of off-patent drugs, it is much harder to develop an innovative product that works better than existing options.

Multiple sclerosis, a hotbed of innovation
For an example of how progress can be made in treating and controlling an autoimmune disease, one need only look at the advances in MS treatment over the last 30 years. More than 20 MS drugs are now on the market. Initially, medicines were only available by infusion at hospital outpatient clinics. Now patients can take their medication as tablets or by injection pen for subcutaneous administration at home. At the same time, the goal of treatment has shifted to preventing and delaying relapses. Two-thirds of all MS patients begin medical treatment no later than one year after diagnosis. A look at disease progression statistics highlights the benefit of using this window of opportunity. In the 1980s, disability progression in MS typically put patients in a wheelchair within ten years after disease onset. That interval is now as long as 30 years, during which patients enjoy sustained and stable quality of life.

As medical science continues to evolve, therapeutic approaches targeting underlying metabolic processes are filling research and development pipelines. The last two years have seen a major breakthrough in myasthenia gravis, a rare neuromuscular disease in which misdirected antibodies disrupt nerve-muscle communication and damage the muscle membrane. The result is muscle weakness with difficulty breathing, swallowing and speaking.

Big breakthrough at Argenx ...
We acted early on to gain exposure to companies making clinical and commercial progress with autoimmune therapies. There are currently three companies focused on autoimmune disease indications in our portfolio. The Belgian company Argenx is currently the second-largest position in the portfolio and had a weighting of 10.3% at the end of the third quarter of 2022. We first opened a position in Argenx in early 2018 and added to it during the following twelve months. In the meantime the market capitalization of Argenx has increased more than five-fold to EUR 20 bn. At the end of September 2022, BB Biotech had achieved a paper gain of USD 277.6 mn on this investment.

We were confident that efgartigimod, an antibody for treating generalized myasthenia gravis, would be a commercial success when we first invested in Argenx. Sold under the brand name Vyvgart, efgartigimod is now the first drug ever approved in the US, Europe and Japan for the treatment of this neuromuscular disease. Vyvgart is a biological drug with immunomodulatory activity derived from the Fc fragment of human immunoglobulin G1 (IgG1). Because it is three times smaller than conventional antibodies, it penetrates tissues more easily and is effective at lower doses. Recent clinical trial results show that the subcutaneous version of Vyvgart is not less effective than intravenous dosing, which has been the basis for marketing authorization to date.

Argenx has reported strong sequential quarterly sales growth so far this year. Total sales in the third quarter amounted to USD 227.3 mn, an increase of 76% from the preceding quarter. At the current growth rates, Vyvgart will pass the billion-dollar mark in 2023. What’s more, this incredible start might only be the beginning of a long-lasting growth story. The big opportunity with efgartigimod is to use the same mechanism of action to treat five other autoimmune diseases, including immune thrombocytopenia (ITP), a bleeding disorder caused by platelet decline. If Argenx receives marketing authorization in all of these additional indications, we estimate that the drug's annual sales potential could range between USD 8 and 10 bn.

... and two promising newcomers
Celldex Therapeutics, a US company, has been in BB Biotech's portfolio since the second quarter of 2022. Celldex is exciting because of its most advanced clinical candidate, barzolvolimab (CDX -0159). Barzolvolimob is the first antibody agent designed to inhibit mast cell activation. Mast cells store chemical messengers such as histamine in the body’s natural immune system. Mast cells promote the stimulation of IgE (immunoglobulin E) receptors by the IgE produced by B cells. By attaching to the surface of mast cells, especially in the mucous membranes, IgE can trigger allergies, angioedema and hives (urticaria). CDX-0159 is currently in Phase II clinical trials for the treatment of chronic urticaria. If clinical trial outcomes are favorable, the drug might be approved for other skin conditions and for some gastrointestinal disorders as well.

 We first invested in Kezar Life Sciences in 2018. It most advanced product candidate is KZR-616 for the management of three autoimmune diseases for which no adequate treatment options currently exist. KZR-616, a first-in-class immunoproteasome inhibitor, is thought to prevent the production of pro-inflammatory cytokines while increasing the activity of regulatory T cells. Clinical trials exploring the drug’s efficacy in autoimmune hepatitis, dermatomyositis, polymyositis, and lupus nephritis are underway. Lupus nephritis is a potentially life-threatening autoimmune disease of the kidneys. The only treatment options currently available are immunosuppressants, which are ineffective in many cases. Kezar has reported positive topline data on renal response in this indication.

We expect that targeted new drugs will go some way to addressing the high unmet medical need in autoimmune diseases in the near future. Clinical news flow and a steady high number of product approvals are leading the entire biotech sector higher and sustained strong sales and profit growth is expected to continue in 2023. Stock valuations remain at attractive levels, and we see interesting investment opportunities.

This might also interest you